Nutriband

What Nutriband does

Nutriband Inc. (NASDAQ: NTRB, NTRBW) is a pharmaceutical company developing AVERSA™, an abuse-deterrent transdermal technology platform that incorporates aversive agents into transdermal patches to prevent abuse, misuse, diversion, and accidental exposure of opioid-based and stimulant medications. The lead product candidate is AVERSA Fentanyl, which combines Nutriband's AVERSA technology with Kindeva Drug Delivery's FDA-approved transdermal fentanyl patch under a 505(b)(2) NDA pathway confirmed by FDA; the company projects $80M-$200M in peak annual US sales potential for this product. The AVERSA patent portfolio is granted in 46+ countries including the US, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. Additional pipeline candidates include AVERSA Buprenorphine (opioid dependence), AVERSA Methylphenidate (ADHD), and 4P Therapeutics' transdermal biologics candidates (4P Exenatide for Type 2 diabetes and 4P FSH for infertility).

The company operates through three subsidiaries: 4P Therapeutics (clinical R&D for transdermal delivery of biologics), Pocono Pharmaceutical (contract manufacturing of matrix-coated drug delivery systems and topical formulations — 90% of which was sold to EarthVision Bio in December 2025 for $5M), and Active Intelligence (consumer wellness products including AI kinesiology tape, AI Performance Tape, AI Energy Patches, and AI Sleep sold via Amazon and direct-to-consumer channels). The company generates current revenue primarily from contract manufacturing and consumer wellness tape sales; fiscal year 2025 revenue was approximately $2.14M, with quarterly growth of 50-63% year-over-year in 2025. Go-to-market combines direct enterprise sales for pharmaceutical products, exclusive distribution partners for international markets (Innomedica for Costa Rica), DTC e-commerce for AI Tape, and major-sports-brand licensing (Fit for Life Group covering Reebok, Adidas, New Balance). Headquartered in Orlando, Florida; CEO is co-founder Gareth Sheridan and Chairman is Serguei Melnik.

Name

Nutriband

Legal name

Nutriband Inc.

Website

https://nutriband.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Nutriband Inc. is a NASDAQ-listed pharmaceutical company developing AVERSA™, an abuse-deterrent transdermal patch technology for opioid and stimulant abuse. It operates clinical R&D, contract manufacturing, and consumer wellness subsidiaries while pursuing FDA approval for lead product AVERSA Fentanyl.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Delivery

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• Abuse-deterrent pharmaceuticals
• Transdermal drug delivery
• Contract pharmaceutical manufacturing
• Consumer wellness patches
• Kinesiology tape products

Headquarters

HQ city

Florida

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Contract Manufacturing Services: Pocono Pharmaceutical provides contract development and manufacturing services for matrix-coated drug delivery systems, topical formulations, and cosmetic products. Revenue is generated through manufacturing fees for third-party clients, with growth driven by increasing demand for coated products and sports tape manufacturing.
2. Consumer Wellness Products: Active Intelligence sells AI Tape and wellness products directly to consumers through Amazon and the company's website, targeting the sports recovery and athletic performance market.
3. Clinical Research Services: 4P Therapeutics provides contract R&D services for life sciences and pharmaceutical clients, advancing innovative drug delivery solutions from concept through clinical validation.
4. Pharmaceutical Product Licensing (Future): Upon FDA approval, AVERSA Fentanyl is expected to generate revenue through product sales with peak annual US sales potential of $80 million to $200 million, with additional potential from global markets.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Nutriband develops and commercializes the proprietary AVERSA abuse-deterrent transdermal technology platform, integrating aversive agents into transdermal patches to prevent abuse, misuse, diversion, and accidental exposure of opioids and stimulants. Its lead candidate AVERSA Fentanyl combines this technology with an FDA-approved transdermal fentanyl patch system under a 505(b)(2) NDA pathway. Through its subsidiaries, the company also provides contract pharmaceutical manufacturing and clinical R&D services, and sells consumer sports-recovery and wellness products (AI Tape, AI Performance Tape, AI Energy Patches, AI Sleep).

Product overview

Nutriband operates as a NASDAQ-listed pharmaceutical company (NASDAQ:NTRB, NTRBW) with three revenue-generating subsidiaries: 4P Therapeutics (clinical R&D), Pocono Pharmaceutical (contract manufacturing), and Active Intelligence (consumer wellness products). The company's core technology is the AVERSA™ abuse-deterrent transdermal platform, which incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The lead pharmaceutical product is AVERSA™ Fentanyl, an abuse-deterrent fentanyl patch for chronic pain, with estimated peak US sales of $80M-$200M and regulatory pathway via 505(b)(2) NDA. Additional pipeline products include AVERSA Buprenorphine and AVERSA Methylphenidate for other abuse-prone medications, plus novel transdermal products (4P Exenatide for diabetes, 4P FSH for infertility). The consumer wellness segment under Active Intelligence includes AI-branded kinesiology tapes and wellness patches (AI Performance Tape, AI Energy Patches, AI Sleep) targeting the sports recovery, wellness, and athletic performance markets. Nutriband sold a 90% stake in Pocono Pharmaceutical to EarthVision Bio in December 2025 for $5 million, retaining 10% ownership.

Differentiator

Problem solved

Functional benefit

Brands

• AVERSA: Abuse-deterrent transdermal technology platform that incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential
• 4P Therapeutics
• Active Intelligence
• AI Tape
• AI Performance Tape
• AI Energy Patches
• AI Sleep

Products and services

• AVERSA Fentanyl Abuse-deterrent fentanyl transdermal system designed to reduce abuse and misuse of fentanyl patches for chronic pain management. Targets healthcare providers and chronic pain patients requiring around-the-clock opioid therapy.
• AVERSA Buprenorphine Abuse-deterrent buprenorphine transdermal system under development for opioid dependence treatment with transdermal administration.
• AVERSA Methylphenidate Abuse-deterrent methylphenidate transdermal system for ADHD treatment, expanding AVERSA technology platform to stimulant medications with abuse potential.
• AVERSA Transdermal Technology Platform Core abuse-deterrent transdermal technology platform that incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Patented in 46 countries.
• 4P Exenatide Novel transdermal product candidate for Type 2 diabetes, delivering exenatide (typically administered by injection) through a transdermal patch to improve compliance and therapeutic outcomes.
• 4P FSH Novel transdermal product candidate for infertility, delivering Follicle-Stimulating Hormone through a transdermal patch to improve compliance and therapeutic outcomes.
• AI Kinesiology Tape Consumer sports recovery tape combining traditional kinesiology tape benefits with soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix. Available on Amazon and Activeintell.com for athletes, fitness enthusiasts, and general consumers.
• AI Performance Tape AI-branded next-generation kinesiology and recovery product designed to support athletic performance, mobility, muscle recovery, and active lifestyles. Part of Active Intelligence subsidiary's wellness product portfolio.
• AI Energy Patches Innovative wearable wellness patches formulated to support energy, focus, and daily performance. Scheduled for June 2026 launch at ECRM conference.
• AI Sleep Wellness-focused solution developed to support relaxation, recovery, and improved sleep quality. Scheduled for June 2026 launch at ECRM conference.

Quantifiable outcome

• Potential peak annual US sales of $80 million to $200 million for AVERSA Fentanyl
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, strategic and minor.

• Brand Institute, Inc.coreStrategic or Co-development Partner · 30 March 2026Global leader in pharmaceutical brand name and identity development engaged to develop the worldwide commercial brand name and visual identity for AVERSA Fentanyl. Brand Institute has 75% share of drug name approvals globally and 87% of FDA approved names in 2024.
• Innomedica CCB S.A.strategicChannel Partner/ Reseller/ Distributor · 17 February 2026Exclusive distribution agreement for Costa Rica covering AVERSA Fentanyl (contingent on regulatory approval) and all sports tape products manufactured at Pocono Pharmaceutical/Active Intelligence subsidiary. Innomedica oversees and finances all regulatory approvals for the products.
• Qvanta Group of CompaniesminorStrategic or Co-development Partner · 24 January 2026Non-binding Letter of Intent signed to explore quantum-AI technologies collaboration, representing potential future technology development partnership.
• EarthVision BiostrategicStrategic or Co-development Partner · 29 December 2025Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, with closing expected December 31, 2025. Nutriband shareholders retain 10% stake in EarthVision Bio. EarthVision Bio is developing sustainable products to replace plastic and paper items.
• Kindeva Drug DeliverycoreStrategic or Co-development Partner · 28 October 2025Exclusive product development partnership for AVERSA Fentanyl manufacturing scale-up. Kindeva provides FDA-approved transdermal fentanyl patch technology combined with Nutriband's AVERSA abuse-deterrent technology. The partnership includes shared development costs in exchange for milestone payments and commercial manufacturing process development.
• Fit for Life GroupstrategicChannel Partner/ Reseller/ Distributor · 1 January 2025Exclusive supplier agreement with major sports brand licensee whose collection of partnered brands include Reebok, Adidas, and New Balance. Nutriband began manufacturing kinesiology tape products for these brands.
• Charlotte FCminorGTM or Marketing Partner · 1 January 2024Associate partnership agreement for sports tape products, providing marketing and brand visibility opportunities.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Collegium Pharmaceutical: Collegium Pharmaceutical specializes in abuse-deterrent opioid products including Xtampza ER (extended-release oxycodone) and Nucynta. It is directly comparable to Nutriband as both companies focus on developing abuse-deterrent formulations of opioid medications to address the opioid crisis.
• Mallinckrodt Pharmaceuticals: Mallinckrodt manufactures and markets transdermal fentanyl patches (Duragesic) and other opioid products. As the established manufacturer of generic fentanyl transdermal systems, it represents the closest commercial analogue to Nutriband's AVERSA Fentanyl product.
• Hisamitsu Pharmaceutical: Hisamitsu is a leading Japanese pharmaceutical company specializing in transdermal drug delivery systems, including the Salonpas line of pain relief patches. Hisamitsu acquired Noven Pharmaceuticals and is a direct peer in transdermal patch technology and pain management products.
• Noven Pharmaceuticals: A subsidiary of Hisamitsu specializing in transdermal drug delivery systems, including the Daytrana methylphenidate patch for ADHD. Noven is directly comparable to Nutriband's 4P Therapeutics in developing transdermal formulations of complex molecules.
• Teikoku Seiyaku Co., Ltd. Teikoku Seiyaku is one of the largest manufacturers of transdermal patches globally, including generic fentanyl patches. As a major contract manufacturer of transdermal fentanyl systems, it is a key industry peer to Nutriband/Kindeva in the abuse-deterrent fentanyl patch space.
• Lohmann Therapie-Systeme (LTS): LTS is a German-based developer and manufacturer of transdermal therapeutic systems and oral thin films. Its expertise in transdermal drug delivery, including for peptides and biologics, makes it directly comparable to Nutriband's 4P Therapeutics transdermal platform capabilities.
• Kindeva Drug Delivery: Kindeva Drug Delivery is Nutriband's exclusive co-development partner for AVERSA Fentanyl, providing the FDA-approved transdermal fentanyl patch system. As a CDMO specializing in transdermal drug delivery and inhalation products, Kindeva is both a partner and a directly comparable peer in transdermal manufacturing technology.

Broad incumbents

• Purdue Pharma: Purdue Pharma historically developed and marketed OxyContin and other opioid analgesics. While operating under bankruptcy restructuring, Purdue's history with abuse-deterrent opioid formulations (reformulated OxyContin) makes it a comparable peer in the abuse-deterrent opioid category.
• Teva Pharmaceutical Industries: Teva manufactures generic transdermal fentanyl patches and a broad portfolio of pain management and specialty pharmaceutical products. As a major generic fentanyl patch manufacturer, it represents both a competitor and a potential commercialization partner for Nutriband.

Emerging players

• Pernix Therapeutics: Pernix Therapeutics has historically focused on pain management and CNS specialty pharmaceuticals. As a smaller specialty pharma focused on pain management, it represents an emerging peer in the abuse-deterrent and specialty pain management space where Nutriband competes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks3 records

Key highlights6 records

Customer concentration

• Xx.com/nutriband
• YouTubeyoutube.com/channel/nutriband
• Facebookfacebook.com/Nutriband
• LinkedInlinkedin.com/company/nutriband-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nutriband